Momenta Tumbles on FDA News

Shares of Cambridge, MA-based Momenta Pharmaceuticals (NASDAQ: MNTA) are down more more than 50 percent from yesterday’s close of $13.38 on the news that the company’s lead drug candidate—a generic version of the Sanofi-Aventis blood-thinner Lovenox—has been deemed “not approvable” by the FDA. Momenta is developing the drug in partnership with the Sandoz division of Novartis in an attempt to capture a piece of Lovenox’s $1.9 billion U.S. market. In a press release, Momenta’s CEO said the company believes it has the data necessary to address the FDA’s concerns, which centered on the drug’s effect on the immune system.

Trending on Xconomy